Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fast Track designation
Biotech
Experimental drug scores in ph. 3 for painful sunlight disorders
Tanabe’s dersimelagon has snared both fast track and orphan drug status from the FDA.
Gabrielle Masson
Jan 20, 2026 10:13am
Cell therapy biotech Adicet sheds 30% of staffers
Jul 24, 2025 10:20am
J&J targets rare maternal-fetal disease: 'We're going for this'
Apr 2, 2024 11:23am
Kyverna accelerates into another FDA fast track
Jan 19, 2024 10:26am
Chasing Pfizer, Regenxbio benefits from FDA boost in DMD
Apr 11, 2023 9:45am
Ayala and Advaxis fuse together to pool funds for lead programs
Oct 19, 2022 11:00am
